Nature:LC3相关吞噬过程缺陷或导致全身性红斑狼疮

2016-04-26 佚名 生物谷

一项新的研究中,来自美国圣犹大儿童研究医院等机构的研究人员对小鼠大小差异的随机观察,发现一种消化死亡细胞的被称作LC3相关吞噬(LC3-associated phagocytosis, LAP)的过程发生缺陷可能导致一种类似狼疮的自身免疫疾病。相关研究结果于2016年4月20日在线发表在Nature期刊上,论文标题为“Noncanonical autophagy inhibits the au

一项新的研究中,来自美国圣犹大儿童研究医院等机构的研究人员对小鼠大小差异的随机观察,发现一种消化死亡细胞的被称作LC3相关吞噬(LC3-associated phagocytosis, LAP)的过程发生缺陷可能导致一种类似狼疮的自身免疫疾病。相关研究结果于2016年4月20日在线发表在Nature期刊上,论文标题为“Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells”。

当免疫系统制造靶向病人自身组织的抗体时,狼疮就发生了,这会导致广泛的炎症和威胁生命的组织和器官损伤。狼疮中最为常见的是全身性红斑狼疮(systemic lupus erythematosus, SLE),它影响大约32.2万美国人,主要是年轻女性。

论文共同通信作者、圣犹大儿童研究医院免疫科主任Douglas Green博士说,“我们希望这些发现有助认识一些病人身上发生的这种严重疾病的病因,并且有机会通过开发新方法阻止或降低狼疮特征性的炎症或自身免疫反应来改进治疗。”

LAP确保死亡细胞被巨噬细胞吞噬后正确地消化和处理。2007年,Green和他的同事们发现LAP招募自噬过程中的组分来消化巨噬细胞吞噬的东西。研究人员随后证实这有助完成清除细胞尸体的工作。

论文第一作者兼论文共同通信作者、Green实验室博士后研究员Jennifer Martinez博士之前注意到存在LAP缺陷的小鼠要比没有这种缺陷的小鼠显著小得多。

在这项研究中,研究人员发现存在LAP缺陷的小鼠不仅更小,而且也有增加的炎症、自身免疫抗体和其他的免疫变化(包括导致肾脏损伤的免疫变化),其中这些变化与人们所患的SLE相关联。相反地,常规的自噬过程出现缺陷并不导致这些变化。

当将死亡细胞注射进存在LAP缺陷的小鼠体内时,研究人员发现巨噬细胞正常地作出反应,但是一旦被吞噬,这些死亡细胞不能够被高效地消化。这些存在LAP缺陷的小鼠也拥有水平增加的促进炎症发生的被称作细胞因子的免疫分子,和水平下降的抵抗炎症的白细胞介素10(IL-10)。

反复地接触死亡细胞会加快存在LAP缺陷的小鼠体内出现类似狼疮的疾病症状,包括水平增加的攻击正常组织的自身抗体。在LAP正常发挥功能的小鼠体内,并不存在这样的情形。常规的自噬过程出现缺陷也并不会导致小鼠出现死亡细胞吞噬问题、增加的炎性细胞因子产生或类似狼疮的疾病。

LAP和自噬过程协助细胞隔离和处理威胁。一些相同的蛋白(但并不是所有的蛋白)参与这两种过程。比如,蛋白NOX2是LAP必需的,但是并不是自噬过程必需的,而且缺乏NOX2的个人经常患上SLE。

Green说,“死亡细胞清除发生缺陷与SLE疾病过程相关。之前的研究提示着这个问题可能起源自自噬过程缺陷。在这项研究中,我们证实LAP缺陷导致小鼠出现SLE类似的疾病,而且很可能能够解释之前报道的自噬过程和狼疮之间的遗传关联。”

研究人员已经开始鉴定狼疮患者体内的LAP缺陷,并研究LAP可能在其他的炎性疾病中发挥的作用。

原始出处:

Martinez J, Cunha LD, Park S, Yang M, Lu Q, Orchard R, Li QZ, Yan M, Janke L, Guy C, Linkermann A, Virgin HW, Green DR.Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells.Nature. 2016 Apr 20. doi: 10.1038/nature17950

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881008, encodeId=1053188100867, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 10 05:44:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83311, encodeId=7f8b83311a4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Fri Apr 29 17:04:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83164, encodeId=c98383164f9, content=好难哦,看得累, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Thu Apr 28 09:55:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387170, encodeId=9850138e17005, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436075, encodeId=a98714360e5ee, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=)]
    2017-01-10 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881008, encodeId=1053188100867, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 10 05:44:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83311, encodeId=7f8b83311a4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Fri Apr 29 17:04:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83164, encodeId=c98383164f9, content=好难哦,看得累, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Thu Apr 28 09:55:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387170, encodeId=9850138e17005, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436075, encodeId=a98714360e5ee, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=)]
    2016-04-29 卡莲

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1881008, encodeId=1053188100867, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 10 05:44:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83311, encodeId=7f8b83311a4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Fri Apr 29 17:04:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83164, encodeId=c98383164f9, content=好难哦,看得累, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Thu Apr 28 09:55:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387170, encodeId=9850138e17005, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436075, encodeId=a98714360e5ee, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=)]
    2016-04-28 那夏花开

    好难哦,看得累

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1881008, encodeId=1053188100867, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 10 05:44:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83311, encodeId=7f8b83311a4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Fri Apr 29 17:04:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83164, encodeId=c98383164f9, content=好难哦,看得累, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Thu Apr 28 09:55:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387170, encodeId=9850138e17005, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436075, encodeId=a98714360e5ee, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881008, encodeId=1053188100867, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 10 05:44:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83311, encodeId=7f8b83311a4, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Fri Apr 29 17:04:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83164, encodeId=c98383164f9, content=好难哦,看得累, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160307/IMG56DD346053F0D5538.jpg, createdBy=7bed1697174, createdName=那夏花开, createdTime=Thu Apr 28 09:55:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387170, encodeId=9850138e17005, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436075, encodeId=a98714360e5ee, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 28 05:44:00 CST 2016, time=2016-04-28, status=1, ipAttribution=)]
    2016-04-28 zhouqu_8

相关资讯

Sci Transl Med:miR-7可能成为狼疮治疗新靶点

北京协和医院风湿免疫科张烜教授研究团队经过5~6年的基础研究,在国际上首次发现PTEN蛋白在系统性红斑狼疮(SLE)中的致病机制,同时发现调控miR-7可通过纠正PTEN缺陷,恢复SLE中B细胞的表达和功能。相关研究结果近日发表在《科学·转化医学》杂志上,为治疗SLE提供了新靶点。SLE是一种多发于育龄期妇女的自身免疫性疾病,发病机制非常复杂,国际上仅有一个针对靶点的药物获批用于临床,远没有满足S

ICSLE:狼疮患者的心血管风险

  阿根廷布宜诺斯艾利斯——众所周知,诸如Framingham风险评分之类的传统工具会低估系统性红斑狼疮(SLE)患者的心血管风险。在日前举行的国际系统性红斑狼疮大会上,约翰霍普金斯大学的Michelle Petri博士的报告为一种新的10年心血管事件(CVE)风险估算工具提供了支持。   这种新工具综合了传统系血管危险因素(年龄、性别、高血压、高血脂、吸烟、糖尿病和体重指数)与3种狼疮特异因素

Arch Dermatol:吸烟可能加重皮肤狼疮病情

11月21日,美国《皮肤病学文献》(Arch Dermatol)上刊登的一项研究显示,当前吸烟的皮肤红斑狼疮(CLE)患者,比不吸烟CLE患者的病情更糟糕,生活质量更差,且联合应用羟氯喹和米帕林治疗者较多。 该研究纳入218例有CLE或系统性红斑狼疮(SLA)以及狼疮非特异性皮肤病变的患者。主要转归指标为CLE病变面积和严重度指数(CLASI)分值,用以评估疾病的严重性和治疗反应,用Skinde

Int Med News:重视生物制剂对狼疮的作用

  阿根廷布宜诺斯艾利斯——目前获准用于治疗系统性红斑狼疮(SLE)的生物制剂主要局限于贝利木单抗,有关阿贝西普或利妥昔单抗对SLE或狼疮性肾炎疗效的令人信服的研究证据还较少。不过在国际系统性红斑狼疮大会上,一些研究者认为,对于这3种生物制剂应抱以乐观态度。   斯德哥尔摩卡罗林斯卡研究所的Ronald F. van Vollenhoven博士对一项拟于6月在欧洲抗风湿病联盟年会上公布的生物制剂

A&R:全人源化抗IFN-α单克隆抗体西法木单抗治疗SLE安全有效

来自美国巴尔的摩约翰斯·霍普金斯大学医学院的Michelle Petri等人进行了一项研究,该研究的目的是评价中至重度的成人系统性红斑狼疮(SLE)患者多次静脉(IV)使用西法木单抗安全性和耐受性。研究结果在线发布在2013年4月的ARTHRITIS & RHEUMATISM(关节炎与风湿病)上。研究者发现,该项针对西法木单抗的观察性安全性/耐受性和临床活动的研究结果支持其可能进一步发展为